Navigation Links
OHSU Cancer Instutute researchers find abnormalities in gene for melanoma
Date:5/29/2008

PORTLAND, Ore. New research from the Oregon Health & Science University Cancer Institute about mutations in melanoma may bring a wellspring of hope to many patients.

Researchers have discovered that there are several different kinds of DNA abnormalities that can occur in a gene called the KIT gene. These abnormalities are associated with different kinds of acral and mucosal melanomas, which are less common, but highly malignant forms of skin cancer. Acral melanomas are found on the palms of hands, the soles of feet and under nails. Mucosal melanomas are found in the mucous membranes of some organs of the body.

If scientists can figure out the mutation, effective treatments can follow, explained Michael Heinrich, M.D., co-principal investigator, OHSU Cancer Institute member and head of the Hematology and Medical Oncology Section at the Portland Veterans Affairs Medical Center. The co-investigator is Christopher Corless, M.D., Ph.D., OHSU Cancer Institute member.

The research will be presented Sunday, June 1, at 5 p.m. during the annual American Society of Clinical Oncology in Chicago.

This study builds on recent research about the first instance in which a womans metastatic melanoma was driven into remission by the targeted therapy drug, Gleevec, which was developed at the OHSU Cancer Institute. Previously there had been few effective treatments for melanoma patients with metastatic disease. But not all melanomas respond so successfully to Gleevec.

In the current study, Heinrich and colleagues studied 129 samples gathered from people with different types of melanoma and found that there is a high rate of mutations in these cancers.

This means that if we can find the melanoma early, it can be screened to see what type of mutations are present, and eventually you can get the right medication or treatment, Heinrich said.

Heinrich explained that it is similar to testing of breast cancer tumors to decide if patients should receive specific treatments such as hormonal inhibitors and/or the drug Herceptin. He predicts that drugs to treat the mutations found in melanomas could be developed in as little as 18 months.

In the very near future, we can do DNA testing of melanomas to better know exactly what is driving the growth of the cancer and select the best treatment. When we know what is wrong, we can do something to fix it, Heinrich said.

The same KIT mutations as those found in gastrointestinal stromal tumors (GIST) are present in mucosal and acral melanomas. Gleevecs effectiveness against tumors with KIT mutations was first demonstrated by Heinrich. Recent studies have found KIT mutations in 11 percent of acral melanomas 21 percent of mucosal melanomas and 17 percent of melanomas arising in sun-damaged skin.

Melanoma is found predominantly in skin but also in the bowel and the eye. It is the most serious type of cancer of the skin. Each year in the United States, more than 53,600 people learn they have melanoma and the percentage of people who develop melanoma has more than doubled in the past 30 years, according to the National Cancer Institute.


'/>"/>

Contact: Christine Decker
deckerch@ohsu.edu
503-494-8231
Oregon Health & Science University
Source:Eurekalert

Related medicine news :

1. Enzyme may hold key to improved targeting of cancer-fighting drugs
2. Diabetes doubles liver cancer risk for patients with advanced hepatitis C
3. OHSU Cancer Institute researchers find many stomach cancer patients are not gertting best therapy
4. Certain Tests in ERs Raise Cancer Risk for Some
5. Combination of 2 novel anti-cancer agents may help fight CML resistant to current therapy
6. Initiative Links Celebrities to Cancer Research
7. USC researchers identify genetic markers that predict efficacy of novel cancer drug
8. Breast-Specific Gamma Imaging (BSGI) Found to Be Highly Sensitive for Early Stage Breast Cancer
9. Susan G. Komen for the Cure(R) Celebrity Ambassadors to Convene in Nations Capital to Help Race for the Cure, End Breast Cancer Forever
10. American Cancer Society, Patient Advocate Foundation Announce Free, Personalized Assistance for Cancer Patients
11. USC study finds sex, age and ethnicity assciated with colorectal cancer survival
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... M&S ... Certificate of Conformity for the Smart System® 20/20. CE Certification builds upon M&S's ... standards and specifications such as ANSI, ISO and proven test methods used in ...
(Date:3/27/2017)... PA (PRWEB) , ... March 27, 2017 , ... ... business simulation -centric training, today announced the launch of a new research ... strategy, having the skills needed to execute that strategy, and the actual success ...
(Date:3/27/2017)... ... March 27, 2017 , ... According to the American Cancer ... stages, is more than 95%. Once the cancer spreads to other organs, bones, or ... find out how to avoid this latter group, tune in to Lifestyle Magazine ...
(Date:3/27/2017)... Texas (PRWEB) , ... March 27, 2017 , ... ... at the GTEC Orange facility from 8:00am-10:00am on Monday, April 3rd to commemorate ... and will be an opportunity for area-residents to celebrate two great years while ...
(Date:3/25/2017)... PA (PRWEB) , ... March 25, 2017 , ... Getting ... as a public relations partner. , All through the year, Garden Media aims ... press releases, working with key influencers and pitching client’s key messages to ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... , March 27, 2017  ImMAGE Biotherapeutics (OTCMKTS: ... immunotherapy successfully passed early toxicology and efficacy studies. The ... to target a specific protein, MAGE A, in an ... breast cancer. After 4 weeks of ... to show very little toxicity in a full toxicology ...
(Date:3/27/2017)... , March 27, 2017  Sanderling Ventures, portfolio ... Ethicon, a division of Johnson & Johnson. Torax manufactures ... the treatment of gastro-esophageal reflux disease (GERD). The ... (MSA) technology and the procedure is currently available ... Torax Medical was founded by Sanderling Ventures, ...
(Date:3/27/2017)... TEL AVIV, Israel , March 27, 2017 ... focused on oncology and immunology, announced today that AGI-134, an ... recently announced acquisition of Agalimmune Ltd., will be featured at ... Meeting in Washington, DC to ... ...
Breaking Medicine Technology: